Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Joins UCSF Technology Development Program

NEW YORK (GenomeWeb) – Sigma-Aldrich announced today that it has signed a deal to participate in reviewing and consulting on technology development projects from the University of California, San Francisco's Catalyst Program.

The program is designed to support the translation of early biomedical discoveries made at the university into commercial products, and includes a number of funding opportunities for the development of therapeutics, diagnostics, medical devices, and digital health products. 

As part of the arrangement, a Sigma-Aldrich representative will participate in the grant awards process, as well as provide technical insight and market guidance to enable the translation of basic research into marketable research tools and reagents.  

"We hope that Sigma-Aldrich's partnership with the UCSF Catalyst Program will make advanced technologies readily available to translational researchers and speed the development of therapies to improve the quality of life," Sean Muthian, director of strategic marketing at Sigma-Aldrich, said in a statement. "In addition, our commitment to standardizing the manufacture, delivery, and use of these tools may help address some of the challenges of reproducibility with home-brewed research materials."